PHYSIO-CONTROL LIFEPAK 300 PRODUCTION LINE REINSPECTION
This article was originally published in The Gray Sheet
Executive SummaryPHYSIO-CONTROL LIFEPAK 300 PRODUCTION LINE REINSPECTION is scheduled for the week of Jan. 3, according to FDA staffers. Physio-Control is not estimating when it will resume distribution of the Lifepak 300 but expects the FDA inspection of production lines to last from one to three weeks. The company also expects it will have to respond to FDA follow-up questions after the inspection.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.